Resumen
La prevalencia de enfermedades cardiovasculares aumenta con la edad. Los cambios cardiovasculares propios del envejecimiento y la frecuencia de enfermedades que evolucionan a ellas en este grupo etario explican esta asociación. Es en ese segmento de la población donde resulta más complejo el manejo de los pacientes, debido a dificultades en el diagnóstico, restricción en procedimientos invasivos, escasa representación en ensayos clínicos y mala tolerancia a los tratamientos debido a la alta comorbilidad y a las interacciones en el contexto de polifarmacia.
Palabras clave
Anciano
Insuficiencia cardíaca
Fibrilación auricular
Cardiopatía isquémica
Abstract
The prevalence of cardiovascular disease increases with age. Age-related cardiovascular changes and the frequency of conditions that progress to these diseases in this age group explain this association. Patients in this segment of the population are more difficult to manage due to diagnostic difficulties and restrictions for invasive procedures. These patients are underrepresented in clinical trials and have poor tolerance to treatment because of their many comorbidities and interactions in the context of polypharmacy.
Keywords
Elderly patient
Heart failure
Atrial fibrillation
Ischaemic heart disease
Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, M. Cushman, Writing Group Members, et al.
Heart disease and stroke statistics-2016 Update: a report from the American Heart Association.
Circulation., (2016), 133 pp. e38-e360
[2]
Natural history of asymptomatic left ventricular systolic dysfunction in the community.
Circulation., (2003), 108 pp. 977-982
[3]
The natural history of congestive heart failure: the Framingham study.
N Engl J Med., (1971), 285 pp. 1441-1446
[5]
Med Clin N Am., (2011), 95 pp. 439-461
[7]
C.W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr., M.H. Drazner, et al.
2013 ACCF/AHA Guideline for the management of heart failure. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol., (2013), 62 pp. e147-e239
[8]
M.D. Flather, M.C. Shibata, A.J. Coats, D.J. Van Veldhuisen, A. Parkhomenko, J. Borbola, et al.
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
Eur Heart J., (2005), 3 pp. 215-225
[11]
C.M. O’Connor, D.J. Whellan, K.L. Lee, S.J. Keteyian, L.S. Cooper, S.J. Ellis, et al.
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.
JAMA., (2009), 301 pp. 1439-1450
[12]
FRAIL-HF, a study to evaluate the clinical complexity of heart failure in nondependent older patients: rationale, methods and baseline characteristics.
Clin Cardiol, (2014), 37 pp. 725-732
[14]
S.S. Chugh, R. Havmoeller, K. Narayanan, D. Singh, M. Rienstra, E.J. Benjamin, et al.
Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study.
Circulation., (2014), 129 pp. 837-847
[15]
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.
Circulation., (2004), 110 pp. 1042-1046
[16]
J.J. Gómez-Doblas, J. Muñiz, J. Alonso Martín, G. Rodríguez-Roca, J.M. Lobos, P. Awamleh, et al.
Prevalencia de fibrilación auricular en España. Resultados del estudio OFRECE.
Rev Esp Cardiol., (2014), 67 pp. 259-269
[17]
50 year trends in atrial fibrillation prevalence, in-cidence, risk factors, and mortality in the Framingham Heart Study: a cohort study.
Lancet., (2015), 386 pp. 154-162
[18]
M.A. Allessie, N.M. de Groot, R.P. Houben, U. Schotten, E. Boersma, J.L. Smeets, et al.
Electropathological substrate of long-standing persistent atrial fibrilla-tion in patients with structural heart disease: longitudinal dissociation.
Circ Arrhythm Electrophysiol., (2010), 3 pp. 606-615
[19]
Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm.
J Am Coll Cardiol., (2013), 61 pp. 852-860
[20]
P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar, B. Casadei, et al.
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
Eur Heart J., (2016), 37 pp. 2893-2962
[25]
La anticoagulación oral en el anciano con fibrilación auricular no valvular.
Rev Esp Geriatr Gerontol., (2015), 50 pp. 134-142
[27]
V. Regitz-Zagrosek, S. Oertelt-Prigione, E. Prescott, F. Franconi, E. Gerdts, A. Foryst-Ludwig, EUGenMed Cardiovascular Clinical Study Group, et al.
Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes.
Eur Heart J., (2016), 37 pp. 24-34
[28]
Reduced colateral circulation to the infarct-related artery in elderly patients with acute myocardial infarction.
J Am Coll Cardiol., (2004), 44 pp. 28-34
[30]
Rationale and design of the GRACE (Global Registry of Acute Coronary Events) project: a multinational registry of patients hospitalized with acute coronary syndromes.
Am Heart J., (2001), 141 pp. 190-199
[31]
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
EuroIntervention., (2012), 8 pp. 672-678
[32]
Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines) bleeding score.
Circulation., (2009), 119 pp. 1873-1882
[33]
R.D. Lopes, K.P. Alexander, S.V. Manoukian, M.E. Bertrand, F. Feit, H.D. White, et al.
Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
J Am Coll Cardiol., (2009), 53 pp. 1021-1030
[34]
M. Roffi, C. Patrono, J.P. Collet, C. Mueller, M. Valgimigli, F. Andreotti, et al.
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
Eur Heart J., (2016), 37 pp. 267-315
[35]
B. Ibañez, S. James, S. Agewall, M.J. Antunes, C. Bucciarelli-Ducci, H. Bueno, et al.
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).
Eur Heart J., (2018), pp. 119-177
[36]
A review of current diagnosis, investigation, and management of acute coronary syndromes in elderly patients.
Cardiol Ther., (2015), 4 pp. 95-116
[37]
Recommendations for the use of cardiac troponin measurement in acute cardiac care.
Eur Heart J., (2010), 31 pp. 2197-2204
[39]
F1000Res, (2017), 6 pp. 1791
[40]
A. Mischie, C. Andrei, C. Sinescu, G.N. Bajraktari, E. Ivan, G. Chatziathanasiou, et al.
Antithrombotic treatment tailoring and risk score evaluation in elderly patients diagnosed with an acute coronary síndrome.
J Geriatr Cardiol., (2017), 14 pp. 442-456
